BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37067377)

  • 1. Human Antibody V
    Chu X; Li W; Hines MG; Lyakhov I; Mellors JW; Dimitrov DS
    Mol Pharm; 2023 May; 20(5):2754-2760. PubMed ID: 37067377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human antibody V
    Chu X; Li W; Hines MG; Lyakhov I; Mellors JW; Dimitrov DS
    Front Oncol; 2023; 13():1194972. PubMed ID: 37876962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human antibodies targeting ENPP1 as candidate therapeutics for cancers.
    Chu X; Baek DS; Li W; Shyp T; Mooney B; Hines MG; Morin GB; Sorensen PH; Dimitrov DS
    Front Immunol; 2023; 14():1070492. PubMed ID: 36761762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
    Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
    Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.
    Rose AA; Annis MG; Dong Z; Pepin F; Hallett M; Park M; Siegel PM
    PLoS One; 2010 Aug; 5(8):e12093. PubMed ID: 20711474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fusion phage libraries displaying VH or single-chain Fv antibody fragments derived from the antibody repertoire of a vaccinated melanoma patient as a source of melanoma-specific targeting molecules.
    Cai X; Garen A
    Proc Natl Acad Sci U S A; 1997 Aug; 94(17):9261-6. PubMed ID: 9256470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
    Kuan CT; Wakiya K; Dowell JM; Herndon JE; Reardon DA; Graner MW; Riggins GJ; Wikstrand CJ; Bigner DD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1970-82. PubMed ID: 16609006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
    Rose AA; Annis MG; Frederick DT; Biondini M; Dong Z; Kwong L; Chin L; Keler T; Hawthorne T; Watson IR; Flaherty KT; Siegel PM
    Clin Cancer Res; 2016 Dec; 22(24):6088-6098. PubMed ID: 27515299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gpnmb/osteoactivin: an indicator and therapeutic target in tumor and nontumorous lesions.
    Zhuo H; Zhou L
    Pharmazie; 2016 Oct; 71(10):555-561. PubMed ID: 29441921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
    Naumovski L; Junutula JR
    Curr Opin Mol Ther; 2010 Apr; 12(2):248-57. PubMed ID: 20373269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.
    Zhou LT; Liu FY; Li Y; Peng YM; Liu YH; Li J
    Neoplasma; 2012; 59(1):1-5. PubMed ID: 22017590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.
    Maric G; Rose AA; Annis MG; Siegel PM
    Onco Targets Ther; 2013; 6():839-52. PubMed ID: 23874106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.
    Kuan CT; Wakiya K; Keir ST; Li J; Herndon JE; Pastan I; Bigner DD
    Int J Cancer; 2011 Jul; 129(1):111-21. PubMed ID: 20824708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
    Yardley DA; Weaver R; Melisko ME; Saleh MN; Arena FP; Forero A; Cigler T; Stopeck A; Citrin D; Oliff I; Bechhold R; Loutfi R; Garcia AA; Cruickshank S; Crowley E; Green J; Hawthorne T; Yellin MJ; Davis TA; Vahdat LT
    J Clin Oncol; 2015 May; 33(14):1609-19. PubMed ID: 25847941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
    Bendell J; Saleh M; Rose AA; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R; Keler T; Davis T; Vahdat L
    J Clin Oncol; 2014 Nov; 32(32):3619-25. PubMed ID: 25267761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells.
    Tomihari M; Chung JS; Akiyoshi H; Cruz PD; Ariizumi K
    Cancer Res; 2010 Jul; 70(14):5778-87. PubMed ID: 20570888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GPNMB expression in uveal melanoma: a potential for targeted therapy.
    Williams MD; Esmaeli B; Soheili A; Simantov R; Gombos DS; Bedikian AY; Hwu P
    Melanoma Res; 2010 Jun; 20(3):184-90. PubMed ID: 20375921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
    Biondini M; Kiepas A; El-Houjeiri L; Annis MG; Hsu BE; Fortier AM; Morin G; Martina JA; Sirois I; Aguilar-Mahecha A; Gruosso T; McGuirk S; Rose AAN; Tokat UM; Johnson RM; Sahin O; Bareke E; St-Pierre J; Park M; Basik M; Majewski J; Puertollano R; Pause A; Huang S; Keler T; Siegel PM
    Oncogene; 2022 Mar; 41(12):1701-1717. PubMed ID: 35110681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoprotein non-metastatic melanoma protein B functions with growth factor signaling to induce tumorigenesis through its serine phosphorylation.
    Wang C; Okita Y; Zheng L; Shinkai Y; Manevich L; Chin JM; Kimura T; Suzuki H; Kumagai Y; Kato M
    Cancer Sci; 2021 Oct; 112(10):4187-4197. PubMed ID: 34327762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.